Scientists have long used a powerful gene-editing tool called CRISPR to make precise changes to DNA. But a different version of the technology, known ...

Enanta Pharmaceuticals, Inc. announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced ...

Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab –– Additional analyses of secondary ...

A cross-sectional study in Gabon found that people with circulating Loa loa microfilariae showed significantly reduced ...

This interactive dashboard provides a weekly integrated epidemiological summary for influenza, respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for ...

Variant classification serves as an important communication tool for alerting EU/EEA countries about the emergence of SARS-CoV-2 variants with concerning properties likely to impact the ...

A new case report documents 127 days of persistent SARS-CoV-2 RNA positivity in a woman with chronic lymphocytic leukaemia, ...

Kuppalli is an infectious diseases physician and former World Health Organization medical officer. Welcome to the debut of ID Consult, a new STAT column from infectious disease physician Krutika ...

Scientists pinpoint the protien responsible for mutation of the virus. The Delta variant of SARS-CoV-2 was deadlier than any ...

There’s a bit of a chill in the air, pumpkin spice in your coffee and children back to school — which means the threat of ...

There's a bit of a chill in the air, pumpkin spice in your coffee, and children back to school — which means the threat of ...